Phase I trial of a humanized, Fc receptor nonbinding anti-CD3 antibody, hu12F6mu in patients receiving renal allografts

mAbs

Volumn 2, Issue 4, 2010, Pages 449-456

  Li, Jing ^a,b,c   Zhou, Bo ^a,b,c   Shentu, Jianzhong ^d   Du, Li ^a,b   Tan, Min ^a,b   Hou, Sheng ^a,b,c   Qian, Weizhu ^a,b,c   Li, Bohua ^a,b,c   Zhang, Dapeng ^a,b,c   Dai, Jianxin ^a,b,c   Wang, Hao ^a,b,c   Zhang, Xu ^a   Chen, Jianghua ^d   Guo, Yajun ^a,b,c  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c National Engineering Research Center of Antibody Medicine   (China)

^d ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

CD3; Enzyme immunoassay; First dose reaction; Humanized antibody; Pharmacokinetics

Indexed keywords

CYTOKINE; HUMAN MONOCLONAL ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY HU12F6MU; UNCLASSIFIED DRUG; CD3 ANTIGEN; FC RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY; PROTEIN BINDING;

ABNORMAL LABORATORY RESULT; ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG HALF LIFE; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MALE; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; ALLOTRANSPLANTATION; DRUG EFFECTS; FOLLOW UP; GENETICS; GRAFT REJECTION; IMMUNOLOGY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; METABOLISM; MUTATION; POSTOPERATIVE COMPLICATIONS; PROCEDURES; PROTEIN ENGINEERING;

ADMINISTRATION, INTRAVENOUS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; MUTATION; POSTOPERATIVE COMPLICATIONS; PROTEIN BINDING; PROTEIN ENGINEERING; RECEPTORS, FC; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 77958612160     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.12305     Document Type: Article

References (32)

1. Cosimi AB. Clinical development of Orthoclone OKT3. Transplant Proc 1987; 19:7-16.
2. Colonna JO, Goldstein LI, Brems JJ, Vargas JH, Brill JE, Berquist WJ, et al. A prospective study on the use of monoclonal anti-T3-cell antibody (OKT3) to treat steroid-resistant liver transplant rejection. Arch Surg 1987; 112:1120-3.
3. Cosimi AB, Burton RC, Colvin RB, Goldstein G, Delmonico FL, LaQuaglia MP, et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981; 32:535-9.
4. Cosimi AB, Cho SI, Delmonico FL, Kaplan MM, Rohrer RJ, Jenkins RL. A randomized clinical trial comparing OKT3 and steroids for treatment of hepatic allograft rejection. Transplantation Proc 1987; 19:2431-3.
5. Delmonico FL, Auchincloss H, Yang H, Russell PS, Cosimi AB. Indications and outcome of OKT3 therapy after liver, pancreas and renal transplantation. Transplant Proc 1988; 20:249-52.
6. Mahmud N, Klipa D, Ahsan N. Antibody immunosuppressive therapy in solid-organ transplant: Part I. MAbs 2010; 2:148-56.
7. Abramowicz D, Schandene L, Goldman M, Crusiaux A, Vereerstraeten P, De Pauw L, et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47:606-8.
8. Broeders N, Wissing KM, Crusiaux A, Kinnaert P, Vereerstraeten P, Abramowicz D. Mycophenolate mofetil, together with cyclosporin A, prevents anti- OKT3 antibody response in kidney transplant recipients. J Am Soc Nephrol 1998; 9:1521-5.
9. Chatenoud L, Ferran C, Legendre C, Thouard I, Merite S, Reuter A, et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 1990; 49:697-702.
10. Chatenoud L, Ferran C, Reuter A, Legendre C, Gevaert Y, Kreis H, et al. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma. N Engl J Med 1989; 320:1420-1.
11. Kimball JA, Norman DJ, Shield CF, Schroeder TJ, Lisi P, Garovoy M, et al. The OKT3 Antibody Response Study: a multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ transplantation. Transplant Immunol 1995; 3:212-21.
12. Legendre C, Kreis H, Bach JF, Chatenoud L. Prediction of successful allograft rejection retreatment with OKT3. Transplantation 1992; 53:87-90.
13. Norman DJ, Shield CF, Henell KR, Kimball J, Barry JM, Bennett WM, et al. Effectiveness of a second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection. Transplantation 1988; 46:523-9.
14. Woodle ES, Thistlethwaite JR, Jolliffe LK, Fucello AJ, Stuart FP, Bluestone JA. Anti-CD3 monoclonal antibody therapy. An approach toward optimization by in vitro analysis of new anti-CD3 antibodies. Transplantation 1991; 52:361-8.
15. Gaston RS, Deierhoi MH, Patterson T, Prasthofer E, Julian BA, Barber WH, et al. OKT3 first-dose reaction: association with T cell subsets and cytokine release. Kidney Int 1991; 39:141-8.
16. Thistlethwaite JR, Stuart JK, Mayes JT, Gaber AO, Woodle S, Buckingham MR, et al. Complications and monitoring of OKT3 therapy. Am J Kidney Dis 1988; 11:112-9.
17. Adair JR, Athwal DS, Bodmer MW, Bright SM, Collins AM, Pulito VL, et al. Humanization of the murine anti-human CD3 monoclonal antibody OKT3. Hum Antibodies Hybridomas 1994; 5:41-7.
18. Cole MS, Anasetti C, Tso JY. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells. J Immunol 1997; 159:3613-21.
19. Xu D, Alegre ML, Varga SS, Rothermel AL, Collins AM, Pulito VL, et al. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol 2000; 200:16-26.
20. Wong JT, Colvin RB. Bi-specific monoclonal antibodies: selective binding and complement fixation to cells that express two different surface antigens. J Immunol 1987; 139:1369-74.
21. Li BH, Wang H, Dai JX, Ji JJ, Qian WZ, Zhang D, et al. Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions. Immunology 2005; 116:487-98.
22. Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 2001; 13:1551-9.
23. Brambell FW, Hemmings WA, Morris IG. A theoretical model of gammaglobulin catabolism. Nature 1964; 203:1352-4.
24. Junghans RP. Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG. Immunol Res 1997; 16:29-57.
25. Cui W. Human in vivo antigenic modulation of T lymphocytes induced by OKT3 for prevention of transplant rejection. Chinese J Immunol 2001; 17:161-3.
26. Blazar BR, Jenkins MK, Taylor PA, White J, Panoskaltsis-Mortari A, Korngold R, et al. Anti-CD3 epsilon F(ab')2 fragments inhibit T cell expansion in vivo during graft-versushost disease or the primary immune response to nominal antigen. J Immunol 1997; 159:5821-33.
27. Anasetti C, Tan P, Hansen JA, Martin PJ. Induction of specific nonresponsiveness in unprimed human T cells by anti-CD3 antibody and alloantigen. J Exp Med 1990; 172:1691-700.
28. Carpenter PA, Pavlovic S, Tso JY, Press OW, Gooley T, Yu XZ, et al. Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells. J Immunol 2000; 165:6205-13.
29. Smith JA, Tang Q, Bluestone JA. Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets. J Immunol 1998; 160:4841-9.
30. Herold KC, Burton JB, Francois F, Poumian-Ruiz E, Glandt M, Bluestone JA. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1 (Ala-Ala). J Clin Invest 2003; 111:409-18.
31. Henell KR, Bakke A, Kenny TA, Kimball JA, Barry JM, Norman DJ. Degree of modulation of cell-surface CD3 by anti-lymphocyte therapies. Transplant Proc 1991; 23:1070-1.
32. Henell KR, Norman DJ. Monitoring OKT3 treatment: pharmacodynamic and pharmacokinetic measures. Transplant Proc 1993; 25:83-5.